Siemens Fonds Invest GmbH Buys 3,450 Shares of Stryker Co. (NYSE:SYK)

Siemens Fonds Invest GmbH lifted its stake in Stryker Co. (NYSE:SYK) by 23.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 18,349 shares of the medical technology company’s stock after buying an additional 3,450 shares during the period. Siemens Fonds Invest GmbH’s holdings in Stryker were worth $6,607,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Stryker during the fourth quarter valued at approximately $25,000. Rakuten Securities Inc. boosted its stake in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after buying an additional 68 shares in the last quarter. Centricity Wealth Management LLC bought a new stake in Stryker in the 4th quarter valued at $30,000. BankPlus Trust Department acquired a new position in shares of Stryker in the 4th quarter valued at $33,000. Finally, Activest Wealth Management bought a new position in shares of Stryker during the 4th quarter worth about $36,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

Stryker stock opened at $392.42 on Friday. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company’s 50-day moving average is $366.04 and its two-hundred day moving average is $375.15. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a market cap of $149.78 billion, a PE ratio of 50.57, a PEG ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.73 by $0.11. The company had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.50 EPS. Equities analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. The ex-dividend date is Monday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 45.41%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Argus set a $450.00 target price on shares of Stryker in a research note on Monday, February 3rd. Royal Bank of Canada increased their target price on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Sanford C. Bernstein set a $450.00 price target on Stryker in a research note on Monday, May 5th. Wells Fargo & Company upped their price target on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Finally, StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a report on Thursday, March 6th. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $427.05.

Insider Activity at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This represents a 5.53% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.